TORONTO, Aug. 16 /CNW/ - Transition Therapeutics Inc. ("Transition" or
the "Company") (TSX: TTH), announced today that its common shares are expected
to begin trading on the NASDAQ Capital Market on or about Monday, August 20,
2007, under the symbol "TTHI". The Company's common shares will continue to
trade on the Toronto Stock Exchange in addition to NASDAQ. Transition's
Chairman and CEO, Dr. Tony Cruz, is scheduled to ring the opening bell at the
NASDAQ Stock Market at 9:30 a.m. EDT on Monday, August 20, 2007 to commemorate
Transition's listing on the NASDAQ.
"We are pleased to begin trading on the NASDAQ. The achievement of this
milestone recognizes the value of our Alzheimer's and diabetes therapies,"
said Dr. Cruz. "The Company is well positioned for future growth as we look to
broaden and strengthen our product portfolio and attract new partnerships. Our
growing shareholder base includes some of the premier institutional investors
and this listing on the NASDAQ will enhance exposure to the investment
To view the NASDAQ Stock Market Opening Bell Ceremony live on
August 20th, 2007 beginning at 9:15 a.m. EDT, please visit:
Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
AZD-103/ELND005 for the treatment of Alzheimer's disease and regenerative
therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes.
Transition has an emerging pipeline of preclinical drug candidates developed
using its proprietary drug discovery engine. Transition's shares are listed on
the Toronto Stock Exchange under the symbol "TTH". For additional information
about the company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC or otherwise. Press releases may contain forward-looking
statements based on the expectations of our management as of the date of the
release. Actual results may materially differ based on many factors, including
those described in the press releases.
For further information:
For further information: on Transition, visit
www.transitiontherapeutics.com or contact: Dr. Tony Cruz, Chief Executive
Officer, Transition Therapeutics Inc., Phone: (416) 260-7770 x 223,
email@example.com; Elie Farah, Chief Financial Officer,
Transition Therapeutics Inc., Phone: (416) 260-7770 x 203,